1). Overall survival among immune checkpoint inhibitor treated Rheumatoid Arthritis Patients with cancer
2). Steroid and disease modifying anti-rheumatic drug use among immune checkpoint inhibitor treated Rheumatoid Arthritis Patients with cancer
3). Immune related adverse events among autoimmune patients with cancer treated with immune checkpoint inhibitors
Contact
646 962 5900
Deanna Jannat-Khah
Assistant Professor of Epidemiology in Medicine
Using large datasets and statistical methods, I aim to understand immune related adverse events in immune checkpoint inhibitor treated cancer patients with autoimmune disease.
Patients with autoimmune disease, such as rheumatoid arthritis, were often excluded from clinical trials for immune checkpoint inhibitors (ICI). Information on overall survival, immune related adverse events (irAEs), and treatment of irAEs on ICI treated autoimmune patients is needed to inform both clinicians and patients. To gain insight on these outcomes, I use large datasets, to study the disease course for ICI treated cancer patients with autoimmune disease. Additionally, I use a variety of statistical methods, such as survival analyses (landmark, time dependent covariates) and machine learning methods (random survival forests, survival classification and regression trees) in my research.
Major Focus Areas
Rheumatology
Epidemiology
Oncology
Biography
I am an Assistant Scientist at the Hospital for Special Surgery (HSS), and an Assistant Professor of Epidemiology in the Department of Medicine at Weill Cornell Medical College. I graduated from Emory University with a Bachelor of Science Degree in Biology and a Masters of Science in Public Health in Epidemiology and I received my Doctorate in Public Health from the State University of New York Downstate Medical Center. My educational background is in epidemiology and I have a broad background in various biostatistical methods including analysis of large administrative datasets, survival analysis, machine learning methods (LASSO, random forest, random survival forest, classification and regression trees, etc), meta-analyses, hierarchical models and qualitative analyses. I divide my time between being a biostatistician on rheumatology research projects and being a PI on my own Immune Checkpoint Inhibitor research.
Distinctions
Discovered and named a new bacteria species, Nocardia mikamii
Awarded the HSS Department of Medicine Discovery Grant in 2023 and had funding renewed in 2024
American College of Rheumatology and European Alliance of Associations for Rheumatology, Research Exchange Program participant, Vienna, Austria 2024
